Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Non-Current Liabilities (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Other Non-Current Liabilities data on record, last reported at $20.0 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 767.85% year-over-year to $20.0 million; the TTM value through Dec 2025 reached $20.0 million, up 767.85%, while the annual FY2025 figure was $20.0 million, 767.85% up from the prior year.
  • Other Non-Current Liabilities reached $20.0 million in Q4 2025 per VRDN's latest filing, up from $2.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $20.0 million in Q4 2025 and bottomed at $33000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $2.4 million, with a median of $1.2 million recorded in 2021.
  • The widest YoY moves for Other Non-Current Liabilities: up 3112.12% in 2022, down 64.26% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $1.2 million in 2021, then decreased by 2.98% to $1.2 million in 2022, then dropped by 15.61% to $989000.0 in 2023, then skyrocketed by 133.37% to $2.3 million in 2024, then soared by 767.85% to $20.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $20.0 million in Q4 2025, $2.6 million in Q3 2025, and $2.1 million in Q2 2025.